Cystic fibrosis is a multi-systemic disease related to reduced functional capacity. The distance covered in the 6-min walk test (6MWT) has been known to assess functional capacity, but little is known about other indexes that can be derived. We sought to compare the performance during the 6MWT and the estimated indexes of functional capacity from the 6MWT between subjects with cystic fibrosis (CF) and healthy individuals as well as to assess the relationship among these indexes and disease severity, pulmonary function, and nutritional status in CF.
METHODS:
This cross-sectional study was carried out at a university referral center for CF. It included a group of 55 non-oxygen-dependent CF subjects (CF group) with no acute pulmonary exacerbations and a group of 185 healthy controls (control group). All subjects were submitted to 6MWT and anthropometrics measurements.
RESULTS:
Regarding performance during the 6MWT, the mean values of work, physiological cost index, average velocity, and 6-min walk distance (6MWD) were significantly lower in the CF group than in the control group (work: 21,690.58 ± 10,427.77 vs 26,057.51 ± 11,228.49 m × kg [P = .007]; physiological cost index: 0.31 ± 0.19 vs 0.37 ± 0.17; average velocity: 94.71 ± 12.89 vs 104.55 ± 9.13 m/min [P < .001]; and 6MWD: 568.02 ± 76.31 m versus 627.54 ± 54.81 m [P < .001]). Subjects with less severe CF had higher 6MWD, work, and average velocity during the 6MWT, compared with subjects with more severe CF (P = .008, P = .01, and P = .007, respectively). There was a correlation between 6MWD, work, average velocity, and disease severity and pulmonary function.
CONCLUSIONS:
Considering the importance of standard measure (6MWD) the in 6MWT, alternative indexes can be useful as complementary outcomes and to provide a better understanding of limiting factors of exercise response in children and adolescents with CF.
MogayzelPJJr, FlumePA. Update in Cystic Fibrosis 2009. Am J Respir Crit Care Med, 2010; 181(6):539–544.
2.
KucaK, KlimovaB, NovotnyM, MaresovaP. Cystic fibrosis revisited: a review study. Med Chem, 2016. [Epub ahead of print].
3.
NarangI, PikeS, RosenthalM, Balfour-LynnIM, BushA. Three-minute step test to assess exercise capacity in children with cystic fibrosis with mild lung disease. Pediatr Pulmonol, 2003; 35(2):108–113.
4.
CoxNS, AlisonJA, ButtonBM, WilsonJW, MortonJM, HollandAE. Physical activity participation by adults with cystic fibrosis: an observational study. Respirology, 2016; 21(3):511–518.
5.
GruetM, BrisswalterJ, MelyL, VallierJM. Use of the peak heart rate reached during six-minute walk test to predict individualized training intensity in patients with cystic fibrosis: validity and reliability. Arch Phys Med Rehabil, 2010; 91(4):602–607.
ArikanH, Yatarİ, Calik-KutukcuE, AribasZ, SaglamM, Vardar-YagilN, et al. A comparison of respiratory and peripheral muscle strength, functional exercise capacity, activities of daily living and physical fitness in patients with cystic fibrosis and healthy subjects. Res Dev Disabil, 2015; 45(46):147–156.
8.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med, 2002; 166(1):111–117.
9.
GulmansVA, van VeldhovenNH, de MeerK, HeldersPJ. The six-minute walking test in children with cystic fibrosis: reliability and validity. Pediatr Pulmonol, 1996; 22(2):85–89.
10.
CarterR, HolidayDB, NwasurubaC, StocksJ, GrothuesC, TiepB. 6-minute walk work for assessment of functional capacity in patients with COPD. Chest, 2003; 123(5):1408–1415.
11.
ChuangML, LinIF, WassermanK. The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. Respir Med, 2001; 95(7):618–626.
12.
GrahamJE, OstirGV, KuoYF, FisherSR, OttenbacherKJ. Relationship between test methodology and mean velocity in timed walk tests: a review. Arch Phys Med Rehabil, 2008; 89(5):865–872.
13.
Bratteby TollerzLU, OlssonRM, ForslundAH, NorrlinSE. Reliability of energy cost calculations in children with cerebral palsy, cystic fibrosis and health controls. Acta Paediatr, 2011; 100(12):1616–1620.
14.
ButlerP, EngelbrechtM, MajorRE, TaitJH, StallardJ, PatrickJH. Physiological cost index of walking for normal children and its use as an indicator of physical handicap. Dev Med Child Neurol, 1984; 26(5):607–612.
15.
MacGregorJ. The objective measurement of physical performance with long-term ambulatory physiological surveillance equipment. In: StottFD, RafteryEB, GouldingL, editors. Proceedings of the Third International Symposium on Ambulatory Monitoring. London: Academic Press; 1979:29–39.
16.
KangaJ, KuhnR, CraigmyleL, HaverstockD, ChurchD. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther, 1999; 21(8):1343–1356.
17.
HafenGM, RanganathanSC, RobertsonCF, RobinsonPJ. Clinical scoring system in cystic fibrosis. Pediatr Pulmonol, 2006; 41(7):602–617.
18.
ShwachmanH, KulczyckiLL. Long term study of one hundred five patients with cystic fibrosis. Am J Dis Child, 1958; 96(18):6–15.
19.
DoeurshukCF, MatthewsLW, TuckerAS, NudelmanH, EddyG, WiseM, SpectorS. A 5 year clinical evaluation of a therapeutic program for patients with cystic fibrosis. J Pediatr, 1964; 65(5):677–693.
20.
SantosCIS, RibeiroJD, RibeiroAF, HesselG. Critical analysis of scoring systems used in the assessment of cystic fibrosis severity: state of the art. J Bras Pneumol, 2004; 30(3):286–298.
21.
PriesnitzCV, RodriguesGH, Stumpf CdaS, ViapianaG, CabralCP, SteinRT, et al. Reference values for the 6-min walk test in healthy children aged 6-12 years. Pediatr Pulmonol, 2009; 44(12):1174–1179.
22.
Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para testes de função pulmonar. J Pneumol, 2002; 28(3):S1–S238.
23.
MillerMR, HankinsonJ, BrusascoV, BurgosF, CasaburiR, CoatesA, et al. ATS/ERS statement: standardisation of lung function testing. Eur Respir J, 2005; 26(2):319–338.
24.
RasekabaT, LeeAL, NaughtonMT, WilliamsTJ, HollandAE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J, 2009; 39(8):495–501.
25.
LandsLC, HeigenhauserGJ, JonesNL. Analysis of factors limiting maximal exercise performance in cystic fibrosis. Clin Sci, 1992; 83(4):391–397.
26.
CoatesAL, BoyceP, MullerD, MearnsM, GodfreyS. The role of nutritional status, airway obstruction, hypoxia, and abnormalities in serum lipid composition in limiting exercise tolerance in children with cystic fibrosis. Acta Paediatr Scand, 1980; 69(3):353–358.
27.
PrasadSA, CernyFJ. Factors that influence adherence to exercise and their effectiveness: application to cystic fibrosis. Pediatr Pulmonol, 2002; 34(1):66–72.
28.
WilkesDL, SchneidermanJE, NguyenT, HealeL, MoolaF, RatjenF, et al. Exercise and physical activity in children with cystic fibrosis. Paediatr Respir Rev, 2009; 10(3):105–109.
29.
NixonPA, JoswiakML, FrickerFJ. A six-minute walk test for assessing exercise tolerance in severely ill children. J Pediatr, 1996; 129(3):362–366.
30.
BoucherGP, LandsLC, HayJA, HornbyL. Activity levels and the relationship to lung function and nutritional status in children with cystic fibrosis. Am J Phys Med Rehabil, 1997; 76(4):311–315.
31.
RogersD, PrasadSA, DoullJ. Exercise testing in children with cystic fibrosis. J R Soc Med, 2003; 96(43):23–29.
32.
Morales-BlanhirJE, Palafox VidalCD, Rosas Romero MdeJ, García CastroMM, Londoño VillegasA, ZamboniM. Six-minute walk test: a valuable tool for assessing pulmonary impairment. J Bras Pneumol, 2011; 37(1):110–117.
33.
CahalinL, PappagianopoulosP, PrevostS, WainJ, GinnsL. The relationship of the 6-min walk test to maximal oxygen consumption in transplant patients with end-stage lung disease. Chest, 1995; 108(2):452–459.
34.
PuhanMA, MadorMJ, HeldU, GoldsteinR, GuyattGH, SchümannHJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J, 2008; 32(3):637–643.
35.
HollandAE, HillCJ, RasekabaT, LeeA, NaughtonMT, McDonaldCF. Updating the minimal importance difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil, 2010; 91(2):221–225.
36.
GeigerR, StrasakA, TremlB, GasserK, KleinsasserA, FischerV, et al. Six-minute walk test in children and adolescents. J Pediatr, 2007; 150(4):395–399.
37.
LammersAE, HislopAA, FlynnY, HaworthSG. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child, 2008; 93(6):464–468.
38.
LiAM, YinJ, AuJT, SoHK, TsangT, WongE, et al. Standard reference for the 6-minute walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med, 2007; 176(2):174–180.
39.
HillK, JenkinsSC, CecinsN, PhilippeDL, HillmanDR, EastwoodPR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil, 2008; 89(9):1782–1787.
40.
KarpmanC, DePewZS, LeBrasseurNK, NovotnyPJ, BenzoRP. Determinants of gait speed in COPD. Chest, 2014; 146(1):104–110.
41.
OrensteinDM, FranklinBA, DoershukCF, HellersteinHK, GermannKJ, HorowitzJG, SternRC. Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. The effects of a three months supervised running program. Chest, 1981; 80(4):392–398.
42.
SelvaduraiHC, McKayKO, BlimkieCJ, CooperPJ, MellisCM, Van AsperenPP. The relationship between genotype and exercise tolerance in children with cystic fibrosis. Am J Respir Crit Care Med, 2002; 165(6):762–765.
43.
AlmajedA, LandsLC. The evolution of exercise capacity and its limiting factors in cystic fibrosis. Paediatr Respir Rev, 2012; 13(4):195–199.
44.
PastréJ, PrévotatA, TardifC, LangloisC, DuhamelA, WallaertB. Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC Pulm Med, 2014; 14:74.
45.
HommerdingPX, BaptistaRR, MakarewiczGT, SchindelCS, DonadioMV, PintoLA, MarosticaPJ. Effects of an educational intervention of physical activity for children and adolescents with cystic fibrosis: a randomized controlled trial. Respir Care, 2015; 60(1):81–87.
46.
HebestreitH, AretsHG, AuroraP, BoasS, CernyF, HulzebosEH, et al. Statement on exercise testing in cystic fibrosis. Respiration, 2015; 90(4):332–351.
